ALSUntangled #82: N-acetylcysteine.

Area of Science:

• Neuroscience
• Pharmacology

Background:

• N-acetylcysteine (NAC) is a glutathione precursor with potential neuroprotective mechanisms relevant to Amyotrophic Lateral Sclerosis (ALS).
• Proposed mechanisms include reducing oxidative stress, neuroinflammation, and mitochondrial dysfunction in ALS.
• Preclinical data on NAC's efficacy in ALS mouse models are conflicting.

Purpose of the Study:

• To evaluate the therapeutic potential of N-acetylcysteine for slowing the progression of Amyotrophic Lateral Sclerosis (ALS).

Main Methods:

• Review of preclinical studies in ALS mouse models.
• Analysis of case studies involving oral or subcutaneous NAC administration in ALS patients.
• Examination of data from completed clinical trials investigating NAC for ALS treatment.

Main Results:

• Preclinical studies yielded inconsistent results regarding motor impairment and survival in ALS mouse models.
• Case studies and clinical trials have not demonstrated convincing benefits or efficacy of NAC in slowing ALS progression.
• ALSUntangled currently does not recommend NAC for slowing ALS progression based on available evidence.

Conclusions:

• N-acetylcysteine exhibits theoretical promise for ALS treatment due to its antioxidant and anti-inflammatory properties.
• Despite theoretical promise, current clinical evidence does not support the use of N-acetylcysteine to slow ALS progression.
• Further research is required to definitively establish the therapeutic role, if any, of N-acetylcysteine in managing ALS.